Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins.
The purpose of this study was to evaluate the extent of overlapping immunogenic peptides between three pharmaceutical biologics and influenza viruses. Clinical studies have shown that subsets of patients with rheumatoid arthritis (RA) develop anti-drug antibodies towards anti-TNFα biologics. We post...
Main Authors: | Benjamin J Andrick, Alexandra I Schwab, Brianna Cauley, Lauren A O'Donnell, Wilson S Meng |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4536234?pdf=render |
Similar Items
-
Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization
by: Dana N. Thornlow, et al.
Published: (2021-10-01) -
Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases
by: N. V. Chichasova
Published: (2016-01-01) -
Immunogenicity of TNF-Inhibitors
by: Sadaf Atiqi, et al.
Published: (2020-02-01) -
Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens
by: Uddipan Kar, et al.
Published: (2022-05-01) -
Beyond MHC binding: immunogenicity prediction tools to refine neoantigen selection in cancer patients
by: Ibel Carri, et al.
Published: (2023-04-01)